ImageneBio Inc (IMA) — Analyst outlook / Analyst consensus target is. Based on 5 analyst ratings, the consensus is bullish — 4 Buy, 1 Hold.
The consensus price target is $1.33, representing a downside of 76.5% from the current price $5.65.
Analysts estimate Earnings Per Share (EPS) of $-13.29 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.02 vs est $-13.29 (beat +92.3%). 2025: actual $-10.76 vs est $-5.57 (missed -93.3%). Analyst accuracy: 0%.
IMA Stock — 12-Month Price Forecast
$1.33
▼ -76.46% Downside
Average Price Target
Based on 5 Wall Street analysts offering 12-month price targets for ImageneBio Inc, the price target is $1.33.
The average price target represents a -76.46% change from the last price of $5.65.
IMA Analyst Ratings
Buy
Based on 5 analysts giving stock ratings to ImageneBio Inc in the past 3 months
EPS Estimates — IMA
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$1.02
vs Est –$13.29
▲ 1,202.7% off
2025
Actual –$10.76
vs Est –$5.57
▼ 48.3% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — IMA
67%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual $0.004B
vs Est $0.004B
▼ 0.0% off
2025
Actual $0.001B
vs Est $0.000B
▲ 66.7% off
Revenue Trend
Revenue has declined over the period shown. Analysts forecast significant revenue growth ahead.
